Daptomycin-associated myopathy induced by concomitant administration of mirabegron
- 125 Downloads
To the Editor,
Daptomycin (DAP) belongs to a new class of antibiotics and possesses bactericidal activity against Gram-positive organisms . Currently, this agent is recommended for the treatment of methicillin-resistant Staphylococcus aureus infections and frequently used in various clinical settings . Muscle toxicity is one of the common adverse drug events associated with DAP administration. Incidence rates of myopathy and rhabdomyolysis among patients receiving DAP are estimated about 2–14% and < 5%, respectively . Coadministration of statin [3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors] and antihistamine with DAP is an independent risk factor for the development of DAP-associated myopathy . However, effects of other drugs are still unknown. We describe a first case of DAP-associated myopathy, which was induced by the concomitant administration of mirabegron.
A 57-year-old woman (body weight, 70.8 kg) developed a high fever without remarkable...
None to report.
Compliance with ethical standards
Conflict of interest
The authors confirm that there are no conflicts of interests to declare.
Informed consent was obtained from the patient.
- 2.Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:e18–55.CrossRefGoogle Scholar
- 4.Tyagi P, Tyagi V. Mirabegron, a β3-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. IDrugs. 2010;13:713–22.Google Scholar
- 5.Sebastianelli A, Russo GI, Kaplan SA, McVary KT, Moncada I, Gravas S, et al. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: comparison with placebo and tolterodine. Int J Urol. 2018;25:196–205.CrossRefGoogle Scholar